Appointed
Prakash Raman
Class II director
OLMA ·
Olema Pharmaceuticals, Inc.
the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026
Ready 8-Ks
50
Latest filing
June 23, 2026, 4:19 PM ET
Top materiality
0.80
Event mix
other_material ×22 · earnings ×14 · other ×9
Sentiment
20 pos · 2 neg · 28 neu
Latest earnings
▲ beat 2026-Q1
Executive change
recent →
Recent 8-K filings for OLMA
Highest-materiality recent filing
Olema Pharma enters Novartis collaboration for Phase 3 breast cancer trial and raises $250M
- Collaboration with Novartis provides ribociclib supply for planned Phase 3 OPERA-02 trial of palazestrant in ER+/HER2- frontline advanced/metastatic breast cancer, initiation expected mid-2025.
- $250M private placement: 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares; gross proceeds ~$250M, closing expected Dec 4, 2024.
-
Four Class III directors elected: Bohen (67.5M for), Garland (66.2M), Larson (50.4M), Rappaport (67.3M).
-
Olema partners with Bayer for OP-3136 + darolutamide Phase 1b/2 in mCRPC; 36 patients, H2 2026 start
Olema and Bayer will evaluate OP-3136 (KAT6 inhibitor) combined with darolutamide in ~36 mCRPC patients.
-
Olema announces Phase 1 data for OP-3136: tumor shrinkage in 13/19 evaluable, no DLTs
OP-3136 monotherapy well-tolerated up to 45 mg; no DLTs, no discontinuations due to TRAEs.
-
Olema reports Q1 net loss $53.1M, cash $505.3M; Phase 3 OPERA-01 data due fall 2026
Cash, equivalents, and marketable securities $505.3M as of March 31, 2026.
-
Olema enters 7-year lease for ~38K sq ft corporate HQ in San Francisco
Lease with KR Oyster Point II, LLC for 38,176 sq ft on 4th and 5th floors.
-
Olema Pharmaceuticals appoints Dr. Prakash Raman to Board of Directors
Dr. Raman appointed as Class II director effective April 28, 2026; term expires at 2028 annual meeting.
-
Olema reports FY2025 net loss of $162.5M; cash $505.4M; OPERA-01 data fall 2026
Net loss Q4 $46.1M, full year $162.5M; R&D expenses $43.2M and $157.7M respectively.
-
Olema CFO/COO Kovacs departs Jan 30; CEO Bohen interim principal financial officer
Shane Kovacs, COO and CFO, leaves Jan 30, 2026; not due to disagreement with company on financial operations.
-
Olema reports preliminary cash >$500M as of Dec 31, 2025
Preliminary unaudited cash, equivalents and marketable securities exceed $500M (subject to year-end close).
-
Olema Pharmaceuticals announces $190M follow-on offering of 10M shares at $19.00
Offering of 10,000,000 shares of common stock at $19.00 per share for gross proceeds of ~$190M.
-
Olema terminates ATM prospectus; no further sales until new filing
Terminated ATM prospectus effective November 18, 2025.
-
Olema Q3 net loss $42.2M; cash $329M; initiates OPERA-02 Phase 3; Pfizer deal
Net loss $42.2M for Q3 2025 vs $34.6M Q3 2024; cash, equivalents and securities $329.0M.
-
Olema reports palazestrant + ribociclib Phase 1b/2 mPFS of 15.5 months in ER+/HER2- MBC
As of July 8, 2025, 72 patients enrolled across 90 mg and 120 mg palazestrant dose cohorts with ribociclib 600 mg.
-
Olema enters clinical trial agreement with Pfizer for palazestrant + atirmociclib phase 1b/2
Phase 1b/2 study to evaluate safety and combinability of palazestrant plus Pfizer’s investigational CDK4 inhibitor atirmociclib in ER+/HER2- metastatic breast cancer.
-
Olema Q2 net loss $43.8M, selects 90 mg palazestrant dose for Phase 3 trials, cash $361.9M
Q2 net loss $43.8M vs $30.4M YoY; increase driven by $10M Aurigene milestone and higher R&D for late-stage trials.
-
Olema shareholders elect three Class II directors, approve say-on-pay, ratify EY
Cynthia Butitta: 44,675,129 for, 11,733,848 withheld; Cyrus Harmon: 43,838,514 for, 12,570,463 withheld; Graham Walmsley: 44,120,432 for, 12,288,545 withheld.
-
Olema Q1 2025: $392.7M cash, net loss $30.4M; palazestrant combo mPFS 13.8 months
Cash, cash equivalents, and marketable securities of $392.7M at March 31, 2025; net loss $30.4M.
-
Olema reports FY2024 net loss $129.5M; cash $434.1M; palazestrant Phase 3 on track
Net loss Q4 $33.6M, FY $129.5M vs. $26.8M and $96.7M in 2023; R&D expense $124.5M FY.
-
Olema Pharmaceuticals posts investor presentation with no material new disclosures
Company made investor presentation available on its website on March 5, 2025.
-
Olema Pharmaceuticals makes investor presentation available; no specific facts disclosed
Company filed Form 8-K with investor presentation dated January 13, 2025.
-
Olema exchanges ~6.07M shares for pre-funded warrants with Bain, Paradigm, BVF
Entered exchange agreements to swap 6,070,000 common shares for pre-funded warrants at $0.0001 exercise price.
-
Olema gets FDA IND clearance for OP-3136; palazestrant combo shows 73% 6-month PFS
FDA cleared IND for KAT6 inhibitor OP-3136; Phase 1 to start early 2025.
-
Olema Pharma enters Novartis collaboration for Phase 3 breast cancer trial and raises $250M
Collaboration with Novartis provides ribociclib supply for planned Phase 3 OPERA-02 trial of palazestrant in ER+/HER2- frontline advanced/metastatic breast cancer, initiation expected mid-2025.
-
Olema Pharma Q3 net loss $34.6M; cash $214.8M; OP-3136 IND on track
Q3 2024 net loss $34.6M vs $21.5M in Q3 2023; GAAP R&D $33.2M (up from $19.5M).
-
Olema targets IND for KAT6 drug OP-3136 in Q4 2024; Phase 1/2 starts 2025
Non-clinical data for OP-3136 (KAT6 inhibitor) to be presented at ENA symposium Oct 23-25, 2024.
-
Olema Q2 net loss $30.4M; cash $239.1M; palazestrant combo shows 85% CBR
Net loss for Q2 2024 was $30.4M vs $20.1M in Q2 2023, driven by increased R&D spending on late-stage trials.
-
Borrowing capacity increased from $50M to up to $100M with $25M immediately available.
-
Olema annual meeting results: directors elected, compensation approved, auditor ratified
Ian Clark elected with 33,874,399 for; Sandra Horning 40,102,098 for; Gorjan Hrustanovic 44,334,757 for.
-
Olema reports interim Phase 1b/2 data: palazestrant + ribociclib shows 85% CBR in ER+/HER2- mBC
Combination well tolerated in 50 patients; no new safety signals and no clinically meaningful drug-drug interaction.
-
Net loss of $31.0M for Q1 2024 vs $28.3M a year ago; cash & equivalents $249.0M.
-
Olema reports FY2023 net loss $96.7M, cash $261.8M; palazestrant Phase 3 underway
Cash, equivalents and marketable securities $261.8M as of Dec 31, 2023; net loss $96.7M for FY2023 vs $104.8M in FY2022.
-
Olema nominates OP-3136, KAT6 inhibitor for breast cancer; IND submission targeted by end of 2024
OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor for ER+ breast cancer.
-
Olema makes investor presentation available for JP Morgan Conference; no financial details disclosed
Presentation furnished as Exhibit 99.1, dated January 8, 2024.
-
Enters ATM agreement with Cowen and Company (TD Cowen) to sell up to $150M of common stock at market prices.
-
Olema furnishes investor presentation at SABCS; no specific data disclosed
Investor presentation dated December 6, 2023 made available on company website.
-
Olema reports positive Phase 1b/2 combo data for palazestrant; Phase 3 OPERA-01 enrolling
Palazestrant + ribociclib (19 patients) well-tolerated; no dose-limiting toxicities, no drug-drug interaction.
-
Olema reports Q3 net loss $21.5M, cash $276.9M; OPERA-01 Phase 3 on track
Net loss $21.5M vs $22.7M YoY; cash, equivalents and marketable securities $276.9M.
-
Palazestrant (OP-1250) median PFS of 4.6 months (CBR 40%) in 86 heavily pretreated metastatic ER+/HER2- breast cancer patients.
-
Olema appoints Scott Garland to board of directors with extensive launch experience
Scott Garland appointed to Olema's Board as Class III director effective Oct 16, 2023.
-
Scott Garland appointed to Board as Class III director effective Oct 16, 2023; term through 2026 annual meeting.
-
Olema and Novartis expand Phase 1/2 combo study of palazestrant + ribociclib to ~60 patients
Amendment adds ~30 patients to dose expansion, increasing study size to about 60 total.
-
Olema raises $130M equity, secures $50M credit facility from SVB
Private placement of 13,211,382 shares at $9.84/share raises ~$130M gross.
-
Olema reports Q2 net loss $20.1M; cash $167.4M; Phase 3 trial on track Q4 2023
Net loss $20.1M for Q2 2023, down from $32.9M in Q2 2022; R&D expenses $18.0M.
-
Sean P. Bohen, Yi Larson, and Andrew Rappaport elected as Class III directors through 2026 with votes 23.5M, 18.0M, and 23.7M for respectively.
-
Olema reports Phase 1b/2 data for OP-1250 + palbociclib in ER+/HER2- mBC
Combination of OP-1250 (up to 120 mg) with palbociclib 125 mg was safe and well-tolerated in 29 patients, with no DDI.
-
Olema Pharma Q1 net loss $28.3M, cash $186M; Phase 3 trial of OP-1250 planned H2 2023
Cash, cash equivalents and marketable securities of $186.0M as of March 31, 2023, expected to fund operations into 2025.
-
Olema confirms no cash deposits or securities at Silicon Valley Bank
Company holds zero cash or securities at Silicon Valley Bank.
-
Olema reports FY2022 net loss of $104.8M, restructures to focus on OP-1250 Phase 3
Net loss of $104.8M for FY2022, vs $71.1M in FY2021.
-
Olema Pharmaceuticals amends bylaws to update stockholder nomination procedures
Board approved amended and restated bylaws effective December 15, 2022.
-
Olema Pharma Q3 net loss $22.7M; cash $222.6M; OP-1250 shows 41% tumor reduction
Net loss $22.7M in Q3 2022 vs $17.7M in Q3 2021; R&D expenses $17.6M GAAP ($14.8M non-GAAP).
Executive changes
Appointed
Scott Garland
Class III Director
OLMA ·
Olema Pharmaceuticals, Inc.
appointed Scott Garland to the Board as a Class III director, effective October 16, 2023
Role change
Peter Kushner
Senior Research Fellow and Co-Founder
OLMA ·
Olema Pharmaceuticals, Inc.
On March 10, 2022, Peter Kushner, Ph.D., Chief Scientific Officer (“CSO”) of Olema Pharmaceuticals, Inc. (the “Company”), and the Company agreed that Dr. Kushner would transition from CSO to Senior Research Fellow and Co-Founder, a non-executive role, effective April 1, 2022.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event other_material